NASDAQ:INNT - Innovate Biopharmaceuticals Stock Price, Forecast & News

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.11). View Innovate Biopharmaceuticals' Earnings History.

Innovate Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Innovate Biopharmaceuticals.

1 brokerages have issued twelve-month price targets for Innovate Biopharmaceuticals' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Innovate Biopharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 1,198.7% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.

Media headlines about INNT stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Innovate Biopharmaceuticals earned a coverage optimism score of 0.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next few days. View News Stories for Innovate Biopharmaceuticals.

Innovate Biopharmaceuticals saw a decrease in short interest in January. As of January 31st, there was short interest totalling 1,680,000 shares, a decrease of 8.2% from the January 15th total of 1,830,000 shares. Based on an average trading volume of 706,600 shares, the short-interest ratio is presently 2.4 days. Approximately 7.3% of the company's shares are sold short. View Innovate Biopharmaceuticals' Current Options Chain.

Some companies that are related to Innovate Biopharmaceuticals include CymaBay Therapeutics (CBAY), ESSA Pharma (EPIX), Clearside Biomedical (CLSD), Cyclerion Therapeutics (CYCN), Aquestive Therapeutics (AQST), REDHILL BIOPHAR/S (RDHL), Xeris Pharmaceuticals (XERS), Millendo Therapeutics (MLND), Zynerba Pharmaceuticals (ZYNE), IMMUTEP LTD/S (IMMP), Northwest Biotherapeutics (NWBO), Chimerix (CMRX), Savara (SVRA), Axovant Gene Therapies (AXGT) and Trillium Therapeutics (TRIL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Axsome Therapeutics (AXSM), Iterum Therapeutics (ITRM), Momo (MOMO), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

Innovate Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.20%). Company insiders that own Innovate Biopharmaceuticals stock include Christopher P Prior, Jay P Madan, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Institutional Ownership Trends for Innovate Biopharmaceuticals.

INNT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Innovate Biopharmaceuticals stock in the last two years include Christopher P Prior, Jay P Madan, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Insider Buying and Selling for Innovate Biopharmaceuticals.

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INNT stock can currently be purchased for approximately $0.77.

Innovate Biopharmaceuticals has a market capitalization of $27.63 million. The company earns $-24,160,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe.View Additional Information About Innovate Biopharmaceuticals.

The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.com/.

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]